FDA Drug Review, Surveillance Offices Agree To Share Safety Authority
Executive Summary
FDA's drug review and drug safety offices have set aside their differences and laid out an agreement that more equally divides regulatory authority on issues related to drug safety
You may also be interested in...
FDA Polled Review Staff On Avandia REMS Changes
Decision to replace the rosiglitazone REMS’ distribution restrictions with prescriber training reflected a consensus opinion shared by leadership in three CDER offices, despite a poll of reviewers who participated in a June advisory committee meeting and favored eliminating the risk management program.
Separate FDA Safety Office Attached To House Report, Still Faces Steep Road
A proposal to establish an independent post-market drug surveillance office at FDA will face tough sledding if it comes up in the House Energy and Commerce Health Subcommittee.
Separate FDA Safety Office Attached To House Report, Still Faces Steep Road
A proposal to establish an independent post-market drug surveillance office at FDA will face tough sledding if it comes up in the House Energy and Commerce Health Subcommittee.